Aerovate Therapeutics (AVTE) Insider Trading & Ownership $2.53 0.00 (0.00%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Aerovate Therapeutics (NASDAQ:AVTE) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage24.90%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)7Amount OfInsider Selling(Last 12 Months)$3.30 M Get AVTE Insider Trade Alerts Want to know when executives and insiders are buying or selling Aerovate Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address AVTE Insider Buying and Selling by Quarter Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Aerovate Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails6/14/2024George A EldridgeInsiderSell15,000$25.03$375,450.00 5/17/2024Hunter GilliesInsiderSell4,000$21.08$84,320.00 5/16/2024Timothy P. NoyesCEOSell10,000$21.58$215,800.00 5/2/2024Marinus VerwijsInsiderSell1,981$21.02$41,640.62 5/1/2024Timothy P. NoyesCEOSell11,357$20.34$231,001.38 4/17/2024Benjamin T DakeInsiderSell6,853$22.37$153,301.61 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 4/16/2024Timothy P. NoyesCEOSell10,000$24.70$247,000.00 4/10/2024George A EldridgeInsiderSell7,500$26.85$201,375.00 4/9/2024David S GrayzelDirectorSell11,882$28.15$334,478.30 4/1/2024Benjamin T DakeInsiderSell3,325$31.97$106,300.25 4/1/2024Timothy P. NoyesCEOSell10,000$30.00$300,000.00 3/27/2024Benjamin T DakeInsiderSell11,068$27.97$309,571.96 3/25/2024Benjamin T DakeInsiderSell3,432$28.01$96,130.32 3/19/2024Marinus VerwijsinsiderSell5,300$26.08$138,224.00 3/13/2024George A EldridgeInsiderSell2,016$25.02$50,440.32 3/11/2024George A EldridgeInsiderSell3,433$25.25$86,683.25 3/8/2024George A EldridgeInsiderSell114$25.00$2,850.00 2/23/2024Hunter GilliesInsiderSell511$19.50$9,964.50 2/20/2024Hunter GilliesInsiderSell3,489$20.23$70,582.47 2/5/2024Ralph NivenInsiderSell4,600$17.45$80,270.00 1/17/2024Hunter GilliesInsiderSell4,000$19.50$78,000.00 1/5/2024Ralph NivenInsiderSell4,600$19.16$88,136.00 12/27/2023Hunter GilliesInsiderSell125$24.50$3,062.50 (Data available from 1/1/2013 forward) AVTE Insider Trading Activity - Frequently Asked Questions Who is on Aerovate Therapeutics's Insider Roster? The list of insiders at Aerovate Therapeutics includes Benjamin T Dake, David S Grayzel, George A Eldridge, Hunter Gillies, Marinus Verwijs, Ralph Niven, Timothy P Noyes. Learn more on insiders at AVTE. What percentage of Aerovate Therapeutics stock is owned by insiders? 24.90% of Aerovate Therapeutics stock is owned by insiders. Learn more on AVTE's insider holdings. Which Aerovate Therapeutics insiders have been selling company stock? The following insiders have sold AVTE shares in the last 24 months: Benjamin T Dake ($1,703,746.76), David S Grayzel ($334,478.30), George A Eldridge ($716,798.57), Hunter Gillies ($465,558.57), Marinus Verwijs ($205,790.43), Ralph Niven ($326,928.50), and Timothy P Noyes ($309,150.00). How much insider selling is happening at Aerovate Therapeutics? Insiders have sold a total of 355,568 Aerovate Therapeutics shares in the last 24 months for a total of $7,773,274.42 sold. Aerovate Therapeutics Key ExecutivesMr. Timothy P. Noyes M.B.A. (Age 62)CEO & Director Compensation: $936.9kMr. George A. Eldridge (Age 61)CFO & Treasurer Compensation: $658.6kMr. Timothy J. Pigot (Age 53)Chief Commercial Officer Compensation: $584.6kDr. Benjamin T. Dake Ph.D. (Age 48)Founder, President, COO & Secretary Compensation: $435.5kDr. Marinus Verwijs Ph.D. (Age 48)Chief Technical Officer Compensation: $439.88kDr. Ralph W. Niven M.B.A. (Age 64)M.R, Ph.D., Pharm.S, Chief Scientific Officer Compensation: $372.33kMr. Hunter Gillies M.D. (Age 58)Chief Medical Officer Compensation: $512.74kMs. Donna DeaHead of Regulatory AffairsMs. Susan FischerExecutive Vice President of Development OperationsMr. Stephen K. YuSenior Vice President of Quality More Insider Trading Tools from MarketBeat Related Companies COMPASS Pathways Insider Trading Foghorn Therapeutics Insider Trading Amylyx Pharmaceuticals Insider Trading Lifecore Biomedical Insider Trading iTeos Therapeutics Insider Trading Eledon Pharmaceuticals Insider Trading UroGen Pharma Insider Trading Rezolute Insider Trading Atea Pharmaceuticals Insider Trading Chimerix Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:AVTE) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
